Nephrotoxicity and efficacy assessment of polymyxin use in 92 transplant patients

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 3, 2013, Pages 1442-1446

  Mostardeiro, Marcelo M ^a   Pereira, Carlos A P ^a   Marra, Alexandre R ^a   Pestana, Jose O M ^a   Camargo, Luis Fernando A ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AZATHIOPRINE; CALCINEURIN INHIBITOR; COLISTIN; CYCLOSPORIN; DEXAMETHASONE; GANCICLOVIR; HYDROCORTISONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; POLYMYXIN B; PREDNISONE; RAPAMYCIN; TACROLIMUS; VANCOMYCIN;

ABDOMINAL INFECTION; ACINETOBACTER BAUMANNII; ACUTE PYELONEPHRITIS; ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BACTERIUM CULTURE; BLOOD CULTURE; BLOODSTREAM INFECTION; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG EFFICACY; ENTEROBACTER; FEMALE; GRAFT RECIPIENT; HEMODIALYSIS; HUMAN; KIDNEY DYSFUNCTION; KIDNEY TRANSPLANTATION; KLEBSIELLA PNEUMONIAE; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MORTALITY; NEPHROTOXICITY; PNEUMONIA; POSTOPERATIVE INFECTION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RENAL GRAFT DYSFUNCTION; RETROSPECTIVE STUDY; RISK FACTOR; SOFT TISSUE INFECTION; SURGICAL INFECTION; TREATMENT DURATION; URINARY TRACT INFECTION; URINE CULTURE;

ADULT; AGED; ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; KIDNEY; KIDNEY FUNCTION TESTS; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PANCREAS TRANSPLANTATION; POLYMYXIN B; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84874065919     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01329-12     Document Type: Article

References (44)

1. Evans ME, Feola DJ, Rapp RP. 1999. Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria. Ann. Pharmacother. 33:960 -967.
2. Lieberson AD, Winter LW, Behnke RH, Martin RR. 1969. Extensive pseudomonal pneumonia ultimately responding to polymyxin therapy. Am. Rev. Respir. Dis. 100:558 -564.
3. Fekety FR Jr, Norman PS, Cluff LE. 1962. The treatment of gramnegative bacillary infections with colistin. The toxicity and efficacy of large doses in forty-eight patients. Ann. Intern. Med. 57:214 -229.
4. Gold GN, Richardson AP Jr. 1966. An unusual case of neuromuscular blockade seen with therapeutic blood levels of colistin methanesulfonate (Coly-Mycin). Am. J. Med. 41:316 -321.
5. Landman D, Georgescu C, Martin DA, Quale J. 2008. Polymyxins revisited. Clin. Microbiol. Rev. 21:449-465.
6. Perkins RL. 1964. Apnea with intramuscular colistin therapy. JAMA 190: 421-424.
7. Navon-Venezia S, Ben-Ami R, Carmeli Y. 2005. Update on Pseudomonas aeruginosa and Acinetobacter baumannii infections in the healthcare setting. Curr. Opin. Infect. Dis. 18:306 -313.
8. Koch-Weser J, Sidel VW, Federman EB, Kanarek P, Finer DC, Eaton AE. 1970. Adverse effects of sodium colistimethate. Manifestations and specific reaction rates during 317 courses of therapy. Ann. Intern. Med. 72:857- 868.
9. Tallgren LG, Liewendahl K, Kuhlbaeck B. 1965. The therapeutic success and nephrotoxicity of colistin in acute and chronic nephropathies with impaired renal function. Acta Med. Scand. 177:717-728.
10. Nankivell BJ, Chapman JR. 2006. Chronic allograft nephropathy: current concepts and future directions. Transplantation 81:643- 654.
11. Ojo AO, Held PJ, Port FK, Wolfe RA, Leichtman AB, Young EW, Arndorfer J, Christensen L, Merion RM. 2003. Chronic renal failure after transplantation of a nonrenal organ. N. Engl. J. Med. 349:931-940.
12. Dobbin C, Maley M, Harkness J, Benn R, Malouf M, Glanville A, Bye P. 2004. The impact of pan-resistant bacterial pathogens on survival after lung transplantation in cystic fibrosis: results from a single large referral centre. J. Hosp. Infect. 56:277-282.
13. Linares L, Cervera C, Cofan F, Ricart MJ, Esforzado N, Torregrosa V, Oppenheimer F, Campistol JM, Marco F, Moreno A. 2007. Epidemiology and outcomes of multiple antibiotic-resistant bacterial infection in renal transplantation. Transplant. Proc. 39:2222-2224.
14. Moreno A, Cervera C, Gavalda J, Rovira M, de la Camara R, Jarque I, Montejo M, de la Torre-Cisneros J, Miguel Cisneros J, Fortun J, Lopez-Medrano F, Gurgui M, Munoz P, Ramos A, Carratala J. 2007. Bloodstream infections among transplant recipients: results of a nationwide surveillance in Spain. Am. J. Transplant. 7:2579 -2586.
15. Garnacho-Montero J, Ortiz-Leyba C, Jimenez-Jimenez FJ, Barrero- Almodovar AE, Garcia-Garmendia JL, Bernabeu-Wittel IM, Gallego- Lara SL, Madrazo-Osuna J. 2003. Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clin. Infect. Dis. 36:1111-1118.
16. Cockcroft DW, Gault MH. 1976. Prediction of creatinine clearance from serum creatinine. Nephron 16:31- 41.
17. Falagas ME, Fragoulis KN, Kasiakou SK, Sermaidis GJ, Michalopoulos A. 2005. Nephrotoxicity of intravenous colistin: a prospective evaluation. Int. J. Antimicrob. Agents 26:504 -507.
18. Kallel H, Bahloul M, Hergafi L, Akrout M, Ketata W, Chelly H, Hamida CB, Rekik N, Hammami A, Bouaziz M. 2006. Colistin as a salvage therapy for nosocomial infections caused by multidrug-resistant bacteria in the ICU. Int. J. Antimicrob. Agents 28:366 -369.
19. Markou N, Apostolakos H, Koumoudiou C, Athanasiou M, Koutsoukou A, Alamanos I, Gregorakos L. 2003. Intravenous colistin in the treatment of sepsis from multiresistant Gram-negative bacilli in critically ill patients. Crit. Care 7:R78 -R83.
20. Ouderkirk JP, Nord JA, Turett GS, Kislak JW. 2003. Polymyxin B nephrotoxicity and efficacy against nosocomial infections caused by multiresistant gram-negative bacteria. Antimicrob. Agents Chemother. 47: 2659-2662.
21. Rios FG, Luna CM, Maskin B, Saenz Valiente A, Lloria M, Gando S, Sosa C, Baquero S, Llerena C, Petrati C, Apezteguia C. 2007. Ventilatorassociated pneumonia due to colistin susceptible-only microorganisms. Eur. Respir. J. 30:307-313.
22. Sobieszczyk ME, Furuya EY, Hay CM, Pancholi P, Della-Latta P, Hammer SM, Kubin CJ. 2004. Combination therapy with polymyxin B for the treatment of multidrug-resistant Gram-negative respiratory tract infections. J. Antimicrob. Chemother. 54:566 -569.
23. Santos MV, Marinho Levin AS, Barone AA, Penco IS E, Arruda EA, Manrique I, Costa SF. 1999. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin. Infect. Dis. 28:1008 -1011.
24. Linden PK, Kusne S, Coley K, Fontes P, Kramer DJ, Paterson D. 2003. Use of parenteral colistin for the treatment of serious infection due to antimicrobial-resistant Pseudomonas aeruginosa. Clin. Infect. Dis. 37: e154-e160.
25. Michalopoulos AS, Tsiodras S, Rellos K, Mentzelopoulos S, Falagas ME. 2005. Colistin treatment in patients with ICU-acquired infections caused by multiresistant Gram-negative bacteria: the renaissance of an old antibiotic. Clin. Microbiol. Infect. 11:115-121.
26. Bergan T, Fuglesang J. 1982. Polymyxin antibiotics: chemical and pharmacokinetic properties. Antibiot. Chemother. 31:119 -144.
27. Kunin CM, Bugg A. 1971. Binding of polymyxin antibiotics to tissues: the major determinant of distribution and persistence in the body. J. Infect. Dis. 124:394-400.
28. Kuntzman R, Jacobson M, Tsai I, Burns JJ, Burchall J, Koch A. 1973. Certain aspects of drug binding to nonplasma proteins as illustrated by studies with cyclizine, chlorcyclizine, and polymyxin B. Ann. N. Y. Acad. Sci. 226:131-147.
29. Dalfino L, Puntillo F, Mosca A, Monno R, Spada ML, Coppolecchia S, Miragliotta G, Bruno F, Brienza N. 2012. High-dose, extended-interval colistin administration in critically ill patients: is this the right dosing strategy? A preliminary study. Clin. Infect. Dis. 54:1720 -1726.
30. Garonzik SM, Li J, Thamlikitkul V, Paterson DL, Shoham S, Jacob J, Silveira FP, Forrest A, Nation RL. 2011. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob. Agents Chemother. 55:3284 -3294.
31. Li J, Milne RW, Nation RL, Turnidge JD, Smeaton TC, Coulthard K. 2003. Use of high-performance liquid chromatography to study the pharmacokinetics of colistin sulfate in rats following intravenous administration. Antimicrob. Agents Chemother. 47:1766 -1770.
32. Zavascki AP, Goldani LZ, Cao G, Superti SV, Lutz L, Barth AL, Ramos F, Boniatti MM, Nation RL, Li J. 2008. Pharmacokinetics of intravenous polymyxin B in critically ill patients. Clin. Infect. Dis. 47:1298 -1304.
33. Bergen PJ, Li J, Nation RL. 2011. Dosing of colistin-back to basic PK/PD. Curr. Opin. Pharmacol. 11:464-469.
34. Cheng CY, Sheng WH, Wang JT, Chen YC, Chang SC. 2010. Safety and efficacy of intravenous colistin (colistin methanesulphonate) for severe multidrug-resistant Gram-negative bacterial infections. Int. J. Antimicrob. Agents 35:297-300.
35. Falagas ME, Rafailidis PI, Ioannidou E, Alexiou VG, Matthaiou DK, Karageorgopoulos DE, Kapaskelis A, Nikita D, Michalopoulos A. Colistin therapy for microbiologically documented multidrug-resistant Gramnegative bacterial infections: a retrospective cohort study of 258 patients. Int. J. Antimicrob. Agents 35:194 -199.
36. Hartzell JD, Neff R, Ake J, Howard R, Olson S, Paolino K, Vishnepolsky M, Weintrob A, Wortmann G. 2009. Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center. Clin. Infect. Dis. 48:1724 -1728.
37. Kasiakou SK, Michalopoulos A, Soteriades ES, Samonis G, Sermaides GJ, Falagas ME. 2005. Combination therapy with intravenous colistin for management of infections due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis. Antimicrob. Agents Chemother. 49:3136 -3146.
38. Kim J, Lee KH, Yoo S, Pai H. 2009. Clinical characteristics and risk factors of colistin-induced nephrotoxicity. Int. J. Antimicrob. Agents 34: 434-438.
39. Mendes CA, Cordeiro JA, Burdmann EA. 2009. Prevalence and risk factors for acute kidney injury associated with parenteral polymyxin B use. Ann. Pharmacother. 43:1948 -1955.
40. Santamaria C, Mykietiuk A, Temporiti E, Stryjewski ME, Herrera F, Bonvehi P. 2009. Nephrotoxicity associated with the use of intravenous colistin. Scand. J. Infect. Dis. 41:767-769.
41. Baines RD Jr, Rifkind D. 1964. Intravenous administration of sodium colistimethate. JAMA 190:278 -281.
42. Olesen S, Madsen PO. 1967. Intravenous administration of sodium colistimethate in urinary tract infections. Curr. Ther. Res. Clin. Exp. 9:283- 287.
43. Bates DW, Su L, Yu DT, Chertow GM, Seger DL, Gomes DR, Dasbach EJ, Platt R. 2001. Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin. Infect. Dis. 32:686-693.
44. Falagas ME, Rizos M, Bliziotis IA, Rellos K, Kasiakou SK, Michalopoulos A. 2005. Toxicity after prolonged (more than four weeks) administration of intravenous colistin. BMC Infect. Dis. 5:1. doi:10.1186/1471-2334 -5-1.